Acelrx pharmaceuticals announces european peer-reviewed publication supporting the benefits of sublingual sufentanil tablets for post-operative pain management in the journal of clinical medicine

Patients reported lower pain scores, required fewer rescue doses and had a shorter hospital stay than patients receiving continuous femoral nerve block this study of patients following knee replacement surgery adds to a growing database supporting the benefits of using sufentanil sublingual tablets for surgical pain management hayward, calif. , dec. 8, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a recent retrospective study published in the journal of clinical medicine special issue "advances in postoperative pain management and postoperative chronic pain".
ACRX Ratings Summary
ACRX Quant Ranking